Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Neurocrine Biosciences Inc's Business Segments
Neurocrine Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 959
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 959 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Product99.5%
- Collaboration Revenue0.5%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 954 | 99.5% |
| Collaboration Revenue | $ 5 | 0.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Neurocrine Biosciences Inc
Neurocrine Biosciences Inc.
is a biopharmaceutical company that is focused on the research, development, and commercialization of treatments for neurological and endocrine-related diseases and disorders.
The company was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences has a strong portfolio of products in various stages of development, including several that have received regulatory approval in the United States and other international markets.
One of its most successful products is Ingrezza, a drug that is used to treat tardive dyskinesia, a condition characterized by involuntary muscle movements.
Ingrezza was approved by the FDA in 2017 and has since become the leading drug in the market for the treatment of tardive dyskinesia.
Neurocrine Biosciences also has several other products in its pipeline, including Ongentys, a drug for the treatment of Parkinson’s disease, which was approved by the FDA in 2020.
In addition to its focus on commercializing drugs for neurological and endocrine disorders, Neurocrine Biosciences also invests heavily in research and development.
The company has a strong commitment to discovering and developing new therapies for conditions that have few or no treatment options.
Overall, Neurocrine Biosciences Inc.
is a leading biopharmaceutical company that has been making significant contributions to the field of medicine by developing innovative treatments for neurological and endocrine-related disorders.
With a strong pipeline of products and a commitment to research and development, the company is well-positioned for future growth and success.
is a biopharmaceutical company that is focused on the research, development, and commercialization of treatments for neurological and endocrine-related diseases and disorders.
The company was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences has a strong portfolio of products in various stages of development, including several that have received regulatory approval in the United States and other international markets.
One of its most successful products is Ingrezza, a drug that is used to treat tardive dyskinesia, a condition characterized by involuntary muscle movements.
Ingrezza was approved by the FDA in 2017 and has since become the leading drug in the market for the treatment of tardive dyskinesia.
Neurocrine Biosciences also has several other products in its pipeline, including Ongentys, a drug for the treatment of Parkinson’s disease, which was approved by the FDA in 2020.
In addition to its focus on commercializing drugs for neurological and endocrine disorders, Neurocrine Biosciences also invests heavily in research and development.
The company has a strong commitment to discovering and developing new therapies for conditions that have few or no treatment options.
Overall, Neurocrine Biosciences Inc.
is a leading biopharmaceutical company that has been making significant contributions to the field of medicine by developing innovative treatments for neurological and endocrine-related disorders.
With a strong pipeline of products and a commitment to research and development, the company is well-positioned for future growth and success.
Neurocrine Biosciences Inc. is a prominent pharmaceutical company committed to the research, development, and commercialization of innovative therapeutics targeting neurological and endocrine disorders. Their extensive portfolio encompasses a range of products categorized into four primary segments: psychiatric disorders, neurological disorders, women’s health, and rare diseases. Each segment includes specialized products designed to address specific medical needs.
1. Psychiatric Disorders
The psychiatric disorders segment focuses on conditions that significantly impact mental health and quality of life. The key products in this category include:
- Ingrezza (valbenazine): Approved by the FDA for the treatment of tardive dyskinesia, Ingrezza is specifically designed to manage involuntary movements associated with this disorder. Tardive dyskinesia often arises as a side effect of long-term use of antipsychotic medications. Ingrezza works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2), thereby reducing the excessive dopaminergic signaling responsible for these involuntary movements.
- Orilissa (elagolix): Utilized for managing endometriosis-related pain, Orilissa operates as an oral gonadotropin-releasing hormone (GnRH) antagonist. By suppressing the bodys estrogen production, this medication helps reduce the pain and symptoms associated with endometriosis, offering significant relief to women suffering from this condition.
Neurological Disorders
This segment emphasizes therapeutic interventions for various neurological conditions, enhancing patients’ quality of life:
- Ongentys (opicapone): Ongentys is a treatment intended to mitigate motor fluctuations in patients with Parkinson’s disease. By inhibiting catechol-O-methyltransferase (COMT), an enzyme that breaks down dopamine, Ongentys enhances the efficacy of levodopa therapy, leading to more stable dopamine levels and improved motor function.
- NBI-74788: Currently in clinical development, NBI-74788 aims to address essential tremor, a common movement disorder characterized by uncontrollable shaking. The focus is on formulating an effective therapy to alleviate the motor symptoms associated with this condition.
Women’s Health
Neurocrine Biosciences addresses critical health issues affecting women through its dedicated product line:
- Opicapone: While primarily indicated in the management of Parkinson’s disease, Opicapone plays a role in reducing motor fluctuations, thus improving the overall quality of life for women facing this neurological challenge.
- NBI-74788: Besides its application in essential tremor, NBI-74788 is also being researched for menstrual-related disorders, including premenstrual dysphoric disorder (PMDD). The efficacy of this drug in treating PMDD opens new avenues for managing debilitating symptoms that affect many women.
Rare Diseases
Neurocrine is also focused on developing therapies for rare and complex health conditions:
- Crinecerfont: This investigational drug is undergoing clinical trials for treating congenital adrenal hyperplasia (CAH), a hereditary condition wherein the adrenal glands produce insufficient cortisol. Crinecerfont is designed to act as a selective CRH receptor antagonist, thereby potentially normalizing adrenal hormone levels and improving clinical outcomes for patients.
Additional Services and Commitments
Beyond its drug portfolio, Neurocrine Biosciences emphasizes a comprehensive array of services to support the full lifecycle of product development and commercialization. This includes:
- Clinical Trial Support: Engaging in rigorous clinical trials to validate the safety and efficacy of new medications.
- Regulatory Support: Navigating the complexities of drug approval processes with appropriate regulatory bodies.
- Medical Affairs: Providing healthcare professionals with the necessary scientific information concerning Neurocrine’s products, ensuring informed decision-making in clinical practice.
- Drug Safety and Pharmacovigilance: Monitoring the safety profiles of marketed products to address any potential adverse effects and ensuring patient safety remains paramount.
Neurocrine Biosciences upholds a strong commitment to research and development, employing innovative technologies and strategic partnerships to enhance patient outcomes and expand the availability of effective treatments for neurological and endocrine disorders. Through its comprehensive focus on specialized products and services, the company aims to make a meaningful impact in the lives of individuals affected by these conditions.
1. Psychiatric Disorders
The psychiatric disorders segment focuses on conditions that significantly impact mental health and quality of life. The key products in this category include:
- Ingrezza (valbenazine): Approved by the FDA for the treatment of tardive dyskinesia, Ingrezza is specifically designed to manage involuntary movements associated with this disorder. Tardive dyskinesia often arises as a side effect of long-term use of antipsychotic medications. Ingrezza works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2), thereby reducing the excessive dopaminergic signaling responsible for these involuntary movements.
- Orilissa (elagolix): Utilized for managing endometriosis-related pain, Orilissa operates as an oral gonadotropin-releasing hormone (GnRH) antagonist. By suppressing the bodys estrogen production, this medication helps reduce the pain and symptoms associated with endometriosis, offering significant relief to women suffering from this condition.
Neurological Disorders
This segment emphasizes therapeutic interventions for various neurological conditions, enhancing patients’ quality of life:
- Ongentys (opicapone): Ongentys is a treatment intended to mitigate motor fluctuations in patients with Parkinson’s disease. By inhibiting catechol-O-methyltransferase (COMT), an enzyme that breaks down dopamine, Ongentys enhances the efficacy of levodopa therapy, leading to more stable dopamine levels and improved motor function.
- NBI-74788: Currently in clinical development, NBI-74788 aims to address essential tremor, a common movement disorder characterized by uncontrollable shaking. The focus is on formulating an effective therapy to alleviate the motor symptoms associated with this condition.
Women’s Health
Neurocrine Biosciences addresses critical health issues affecting women through its dedicated product line:
- Opicapone: While primarily indicated in the management of Parkinson’s disease, Opicapone plays a role in reducing motor fluctuations, thus improving the overall quality of life for women facing this neurological challenge.
- NBI-74788: Besides its application in essential tremor, NBI-74788 is also being researched for menstrual-related disorders, including premenstrual dysphoric disorder (PMDD). The efficacy of this drug in treating PMDD opens new avenues for managing debilitating symptoms that affect many women.
Rare Diseases
Neurocrine is also focused on developing therapies for rare and complex health conditions:
- Crinecerfont: This investigational drug is undergoing clinical trials for treating congenital adrenal hyperplasia (CAH), a hereditary condition wherein the adrenal glands produce insufficient cortisol. Crinecerfont is designed to act as a selective CRH receptor antagonist, thereby potentially normalizing adrenal hormone levels and improving clinical outcomes for patients.
Additional Services and Commitments
Beyond its drug portfolio, Neurocrine Biosciences emphasizes a comprehensive array of services to support the full lifecycle of product development and commercialization. This includes:
- Clinical Trial Support: Engaging in rigorous clinical trials to validate the safety and efficacy of new medications.
- Regulatory Support: Navigating the complexities of drug approval processes with appropriate regulatory bodies.
- Medical Affairs: Providing healthcare professionals with the necessary scientific information concerning Neurocrine’s products, ensuring informed decision-making in clinical practice.
- Drug Safety and Pharmacovigilance: Monitoring the safety profiles of marketed products to address any potential adverse effects and ensuring patient safety remains paramount.
Neurocrine Biosciences upholds a strong commitment to research and development, employing innovative technologies and strategic partnerships to enhance patient outcomes and expand the availability of effective treatments for neurological and endocrine disorders. Through its comprehensive focus on specialized products and services, the company aims to make a meaningful impact in the lives of individuals affected by these conditions.